Apogee Therapeutics, Inc.
APGE
Rangering i aksjer
#2337
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its... Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.
Aksjekurs
$135.07
Sist synkronisert: 2026-09-04
Markedsverdi
$8.36B
Endring (1 dag)
0.00%
Endring (1 år)
152.56%
Land
US
Handel Apogee Therapeutics, Inc. (APGE)
Kategori
Healthcare
Aksjeprishistorikk for Apogee Therapeutics, Inc. (APGE)
Høyeste sluttskurs: $135.07 den 2026-09-01
Laveste sluttskurs: $20.79 den 2023-07-01
Laveste sluttskurs: $20.79 den 2023-07-01
Aksjeprishistorikk for Apogee Therapeutics, Inc. fra 2023 til 2026
Årlig aksjeprisytelse
| År | Ytelse |
|---|---|
| 2026 (TTM) | 17.47% |
| 2025 | 60.85% |
| 2024 | 96.41% |
| 2023 | 0.00% |
Aksjepris for lignende selskaper eller konkurrenter
| Selskap | Aksjepris | Endring 1år% | Land |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $760.15 | 8.04% |
CH
|
